CD29 / Integrin Beta 1 (ITGB1) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 08 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Integrin-Mediated Disease Development.

Target Overview

CD29 (Integrin beta 1, ITGB1) is a transmembrane glycoprotein that forms heterodimers with multiple alpha integrins. Key functional domains include PSI, VWFA, and I-EGF 1 (UniProt P05556). ITGB1 is central to cell adhesion, migration, and signaling in development, immunity, and disease.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for ITGB1 (CD29) drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen Human ITGB1 ECD-Fc Fusion Protein
Co-expression compatible with ITGA4/ITGA5. High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation).		 View ITGB1 Products
Gene Delivery ITGB1 Promise-ORF / Lentivirus Premade Particles
Full-length human ITGB1 with native signal peptide for stable cell line construction.		 View ITGB1 Products
Benchmark Ab Anti-ITGB1 Neutralizing Antibody (Research Grade)
Recombinant positive control for adhesion inhibition assays. Sequence Verified.		 View ITGB1 Products
Validator ITGB1 siRNA Set
For knockdown verification in cell-based adhesion and signaling assays.		 View ITGB1 Products
Related Target A ITGA4 (Integrin Alpha 4 / CD49d)
Forms VLA-4 (α4β1); critical synergistic pathway for multiple sclerosis and inflammatory bowel disease.		 View ITGA4 Products
Related Target B ITGA5 (Integrin Alpha 5 / CD49e)
Forms fibronectin receptor (α5β1); key driver of tumor stroma interaction and therapeutic resistance.		 View ITGA5 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Native Heterodimer Conformation (α/β pairing) ITGB1 ECD-Fc co-expression system; compatible with ITGA4/ITGA5 ECDs for heterodimeric complex purification (>95% purity)
Cross-species cyno/mouse eval Human / Cyno / Mouse ortholog ITGB1 proteins available; Sequence Verified; Endotoxin Controlled; Theoretical MW confirmed
Beta-Integrin Subfamily Off-target Screening Homolog panel: ITGB2, ITGB3, ITGB5, ITGB6 proteins strictly verified by mass spec for selectivity assays
Lack of Functional Controls & Validated Reagents Research-grade neutralizing antibody included; Validated siRNA for specificity checks; Sequence Verified benchmark antibodies
Cell-Based Adhesion & Internalization Lentivirus for stable ITGB1-expressing cell lines (HEK293/U2OS backbone); preserves transmembrane conformation for flow cytometry

Live CD29 / ITGB1 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for CD29 (Integrin Beta 1) therapeutics is intensifying, with major players shifting focus from broad-spectrum integrin inhibition to heterodimer-selective blockade. As first-generation therapies (small-molecule allosteric inhibitors and function-blocking antibodies) advance into early-phase studies, the next wave of R&D explores epitope-specific modalities that spare hematopoietic integrins while aggressively disrupting pathological tissue retention in fibrosis and solid tumor microenvironments. Key areas include overcoming treatment resistance in solid tumors, leveraging CD29 for highly internalized Antibody-Drug Conjugates (ADCs), and pursuing selective heterodimer inhibition (e.g., targeting α5β1 over α4β1).

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Function-Blocking mAb Preclinical biotech pipelines; Academic consortia Solid Tumors, Fibrosis Adhesion Inhibition Assay (Need high-purity ITGB1/ITGA heterodimer Fc)
Small Molecule Allosteric Inhibitor Pliant Therapeutics, Morphic Therapeutic Idiopathic Pulmonary Fibrosis, NASH Selectivity Assay (Need Mutant vs WT ITGB1 and ortholog panel)
ADC / Radioligand Emerging preclinical biotech Oncology (TME targeting) Internalization & Recycling Assay (Need full-length ITGB1 Lentivirus cell line)
Bispecific (α4β1 / αV-directed) Takeda, Biogen (legacy pathway) Autoimmune Disease Heterodimer Validation (Need Cross-reactive Abs against ITGA4-ITGB1 complex)